Screening for carcinoma of the prostate: a GP based study

Br J Urol. 1994 Jul;74(1):64-71. doi: 10.1111/j.1464-410x.1994.tb16549.x.


Objective: To examine the feasibility and acceptability of screening for cancer of the prostate by digital rectal examination (DRE), prostate specific antigen (PSA) determination and subsequent transrectal ultrasound (TRUS) in selected patients in a single general practice in Hertfordshire.

Subjects and methods: A total of 568 of 856 men aged 55 to 70 accepted an invitation for a health check which included screening for prostate cancer. Of these, 80 individuals with either a raised PSA level or an abnormal DRE underwent TRUS. In 29 individuals biopsies were taken, 11 of which confirmed the presence of adenocarcinoma of the prostate giving an overall detected prevalence of 2%. Of the 11 tumours identified by screening, two were T1M0, four were T2M0, two were T3M0 and three were T3M1.

Results: To assess the acceptability of the screening exercise a postal questionnaire was sent to all 568 participants: 83% replied and 69% reported no concern. Of the 67 individuals who had undergone TRUS, 69% reported discomfort. A total of 448 (95%) of respondents declared that they would be prepared to undergo the screening exercise again.

Conclusion: Screening for prostate cancer would seem to be technically feasible and generally acceptable. However, there is a considerable false positive rate in the PSA range 4 ng/ml to 10 ng/ml, particularly among men with clinical evidence of benign prostatic hyperplasia. To establish the true benefit of screening a large-scale prospective controlled study will be necessary.

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / diagnostic imaging
  • Adenocarcinoma / prevention & control*
  • Aged
  • Family Practice*
  • Humans
  • Male
  • Mass Screening / methods*
  • Middle Aged
  • Patient Satisfaction
  • Prostate / diagnostic imaging
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / diagnostic imaging
  • Prostatic Neoplasms / prevention & control*
  • Ultrasonography


  • Prostate-Specific Antigen